69 results about "Pregnenolone" patented technology

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The invention discloses a method for inducing nematode-trapping fungus predatory organ formation, and belongs to the field of applied microorganisms. The method comprises the following specific steps: culturing activated nematode-trapping fungi until spores are generated; washing off the cultured spores, and diluting to obtain a spore suspension with the concentration of 30000-60000 spores / mL; coating the spore suspension into an agar culture medium paved with glass paper, uniformly coating the spore suspension, culturing for 28-36 hours at the temperature of 25-28 DEG C, adding a mixed solution of a predatory organ inducer and water, and continuously culturing for 36-60 hours at the temperature of 25-28 DEG C, so that the nematode-trapping fungi can generate a large number of predatory organs; the predatory organ inducer is one of oleic acid, linoleic acid or pregnenolone. It is found for the first time that a large number of predatory organs can be generated when pregnenolone, oleic acid or linoleic acid is used for inducing nematode-trapping fungi.

The present invention relates to the electrochemical oxidation of allylic C- H bonds in specific compounds to obtain specific α,β unsaturated ketones in the presence of t-butyl hydroperoxide. This process is particularly suitable for the electrochemical oxidation of cholesterol, stigmasterol, campesterol, β-sitosterol, brassicasterol, 25-hydroxycholesterol, 24-hydroxycholesterol, lanosterol, pregnenolone, and the esters thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I)for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.

The present invention relates to the technical field of pharmaceutical compounds and specifically discloses a selenocyanine pregnenol ketamide compound having the following general structural formula: #imgabs0#. The selenocyanine pregnenol ketamide compound of the present invention exhibits strong inhibitory activity against human breast cancer cells, cervical cancer cells, ovarian cancer cells, and human liver cancer cells. Furthermore, the selenocyanine pregnenol ketamide compound of the present invention also exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The selenocyanine pregnenol ketamide compound of the present invention has low toxicity to humans and exhibits strong inhibitory effects against cancer cells and various drug-resistant bacteria at low concentrations. It can be used to prepare cancer treatment drugs and as an antibacterial agent against drug-resistant bacteria.

Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.

The invention discloses a method for increasing the yield of pregnenolone in heterologous synthesis of yarrowia lipolytica. According to the method, a recombinant yarrowia lipolytica strain is constructed, and the construction method is selected from one of the following three methods: on the basis of the recombinant yarrowia lipolytica strain SyBEY12060077, CYP11A1 and an ER positioning sequence KDEL are fused; the CYP11A1 is integrated, and meanwhile, the additional Adx gene expression is increased; the CYP11A1 is integrated, and the CYB5 gene is introduced at the same time. According to the newly constructed strain, acquisition of precursor campesterol and electron transfer of P450 enzyme are improved, so that the overall steroid flux is improved, the yield of heterologous production of pregnenolone is improved, and a research thought is provided for subsequent optimization of metabolic regulation and improvement of synthesis of recombinant yarrowia lipolytica steroids.

The invention discloses a method for improving heterologous synthesis of pregnenolone and progesterone by using yarrowia lipolytica. The invention provides a method for improving the heterologous synthesis of pregnenolone by using yarrowia lipolytica, which comprises the following steps: knocking out an MHY1 gene on the basis of a recombinant yarrowia lipolytica strain SyBEY12090002, and constructing a strain Y1001; the invention relates to a method for improving heterologous synthesis of progesterone by using yarrowia lipolytica, which is characterized in that on the basis of a recombinant yarrowia lipolytica strain SyBEY12090002, 3beta-hydroxysteroid dehydrogenase is introduced, an MHY1 gene is knocked out, and a strain Y1102 is constructed. The MHY1 gene is knocked out from the strain for synthesizing the pregnenolone or the progesterone from the beginning, so that the yield of the pregnenolone or the progesterone synthesized by the recombinant lipolytic yeast strain is improved, the influence of regulating the morphological change of the yarrowia lipolytica on a heterologous synthesis pathway is explored, and a research direction is provided for subsequently improving the yield of the pregnenolone or the progesterone.

The invention discloses a 17beta-pregnenolone-amino-acid ester derivative, the chemical structure of which is as shown in the following formula: # imgabs0. The 17beta-pregnenolone-amino-acid ester derivative disclosed by the invention has an inhibiting effect on human breast cancer cells, human ovarian cancer cells, human breast duct cancer cells and human cervical cancer cells, and can be used for preparing antitumor drugs.

The application relates to the technical field of organic synthesis, and particularly discloses a synthesis process of high-purity pregnenolone, which comprises the following steps: S1, esterification reaction of progesterone and an acylation reagent to obtain product 1; S2, ketalization reaction of the product 1, diol and a dehydrating agent in the presence of a catalyst to obtain product 2; S3, reduction reaction of the product 2 and a reducing agent to obtain product 3; and hydrolysis reaction of the product 3 and an acidic compound to obtain pregnenolone. The synthesized pregnenolone has high purity and yield.

The invention discloses a protein composition and application thereof in production of steroids. The protein combination is composed of a DWF protein, a CYP protein and an HSD protein, the DWF protein is an MtDWF5 protein or an StDWF5 protein, the CYP protein is an MtCYP108 protein, an MtCYP150 protein, a CaCYP108-1 protein, a CaCYP108-2 protein, a CaCYP150 protein or a DpCYP108 protein, and the HSD protein is an MtHSD6 protein, a synMtHSD5 protein, a CaHSD5 protein, a PsHSD5 protein or an SlHSD5 protein. Experiments prove that the protein combination can be used for producing at least one of campesterol, cholesterol, pregnenolone and progesterone by taking 7-dehydrosterol as a substrate. The method has important application value.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize alcohol-soluble species, including nonderivatized hormones. More preferably, the modified oil phase droplets of the MOIW microemulsion directly solubilize nonderivatized hormones. The oil phase droplets of the MOIW microemulsion include DHEA, pregnenolone, and a polyphenol, where a ratio of DHEA to polyphenol is from 1:1 to 12:1 by weight. Methods of supporting and / or increasing bloodstream hormone levels in perimenopausal and postmenopausal females and improving menopausal symptoms also are disclosed.

The utility model relates to the technical field of quantitative dropping of allopregnenolone, in particular to a quantitative dropping device of allopregnenolone, which comprises a base, an L-shaped strip is fixed to the top of the base, a hydraulic cylinder is installed at the bottom of the L-shaped strip, a piston rod is installed at the bottom of the hydraulic cylinder, and a piston piece is installed at the bottom of the piston rod. An external member is fixed on the outer wall of the L-shaped strip, a connecting strip is connected in the external member, and a connecting ring is fixed at one end of the connecting strip; a quantitative tube is connected in the connecting ring; the bottom of the quantitative tube is provided with a dropping tube, the outer wall of the dropping tube is provided with a valve body, the inner wall of the quantitative tube is provided with quantitative scale marks, the outer wall of the sleeve piece is provided with a first connecting hole, and the outer wall of the connecting strip is provided with a second connecting hole. And a manual adding mode is replaced, so that the labor intensity of workers is reduced, and the quantitative dropping precision of the allopregnenolone is also improved.

This invention discloses sterol side-chain cleaving enzymes and 3β-hydroxysteroid dehydrogenases / Δ from different sources. 4,5 Amino acid sequences, coding sequences, and applications of isomerases. This invention, based on synthetic biology and molecular pharmacognosy, explores sterol side-chain cleaving enzymes and 3β-hydroxysteroid dehydrogenases / Δ from different plant sources. 4,5 Isomerases, which will yield sterol side-chain cleavage enzymes and 3β-hydroxysteroid dehydrogenases / Δ 4,5 The coding sequences of the isomerases were constructed into expression cassettes, and using Saccharomyces cerevisiae as the chassis strain, highly efficient pregnenolone or progesterone synthesizing strains were obtained. The pregnenolone yield of the constructed strains reached as high as 14.46±2.16 mg / L, and the progesterone yield reached as high as 32.78±1.84 mg / L. This achieved high-level synthesis of pregnenolone and progesterone by genetic engineering methods, providing an important foundation for the green synthesis of steroid hormones.

The present disclosure relates to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, the methods comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to alleviate one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.

The invention discloses a preparation method of 3-oxo-4-androstene-17 beta-carboxylic acid, and belongs to the technical field of medicine synthesis. According to the invention, pregnenolone is used as an initial raw material, and is oxidized by an oxidant in the presence of a catalyst to obtain 3-oxo-4-androstene-17 beta-carboxylic acid. The method is simple and convenient to operate, mild in reaction condition, low in cost, high in yield and suitable for industrial large-scale production, and has great significance in production of epristeride bulk drugs.

The invention discloses a method for preparing a burenolone precursor through photocatalytic configuration inversion. The invention provides a preparation method of a burenolone precursor, which comprises the following steps of: in a solution containing titanium tetrachloride and alkali, placing pregnenolone (formula I) under a 380nm LED (light-emitting diode) lamp under an open illumination condition, and carrying out reaction as shown in the following formula to obtain the burenolone precursor (formula II), the method has the advantages of high yield, simple synthesis method, greenness and safety.

The invention provides a steroid compound containing a 3-methyl allopregnenolone mother nucleus structure as well as a preparation method, a pharmaceutical composition and application of the steroid compound, and belongs to the technical field of medicines. The invention provides a steroid compound containing a 3-methyl pregnenolone mother nucleus structure, and pharmaceutically acceptable salts, stereoisomers, tautomers, prodrugs, solvates or isotope compounds of the steroid compound. The steroid compound containing the 3-methyl pregnenolone mother nucleus structure has a structure as shown in a formula I. The invention further provides a preparation method of the steroid compound containing the 3-methyl pregnenolone mother nucleus structure. The steroid compound containing the 3-methyl allopregnenolone mother nucleus structure has a strong positive regulation effect on a GABAA receptor, and has potential application to treatment of central nervous system related diseases.

The invention relates to the technical field of organic synthesis, and particularly discloses a synthesis process of high-purity pregnenolone, which comprises the following steps: S1, carrying out esterification reaction on progesterone and an acylation reagent to obtain a product 1; s2, the product 1, diol and a dehydrating agent are subjected to a ketalation reaction in the presence of a catalyst, and a product 2 is obtained; s3, carrying out reduction reaction on the product 2 and a reducing agent to obtain a product 3; and carrying out hydrolysis reaction on the product 3 and an acidic compound to obtain pregnenolone. According to the present invention, the synthesized pregnenolone has high purity and high yield.

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.